MapleStory Expands Game Universe in Neo Part One Update With New Archer Class, Kain
MapleStory , the iconic free-to-play global MMORPG from Nexon, has today launched Neo: Darkness Ascending, Part One of its summer update, the largest content update to the game in 2021. Neo Part One adds an all new area, Cernium, increases the max level to 300, and offers special limited-time events today, in addition to adding a new Nova Archer job, Kain, on June 23.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210610005162/en/
MAPLESTORY EXPANDS GAME UNIVERSE IN NEO PART ONE UPDATE WITH NEW ARCHER CLASS, KAIN (Graphic: Business Wire)
First, a new Nova Archer job – the Darkness Chaser, Kain – joins the game on June 23. Kain is a powerful archer, fighting to recover his lost past after discovering that his organization had deceived him. Using the Whispershot, a one-handed weapon, alongside melee weapons from his Weapon Belt, Kain commands an effective and versatile weapons mastery to inflict critical hits on his enemies.
The border between two worlds has disappeared and Cernium, City of the Gods, has reappeared. New area Cernium is now available in-game and brings new challenges and quests to all players. For an added boost, a special power called Sacred Power is now available to aid in the battle against monsters inhabiting the Grandis Continent. Sacred Power is acquired by equipping Sacred Symbols, which can be enhanced to increase Sacred Power as well as main stats.
Starting today, the maximum character level is increased from 275 to 300 and the amount of EXP required to level up between levels 210-250 has been reduced. The update also includes increased EXP rewards for Arcane River quests, and modifies the character death penalty to a decreased drop rate percentage instead of overall experience lost.
Part One of the Neo Update also brings the new Neo Castle event to MapleStory . Neo Castle, an area shrouded in mystery, was formed when Maple World and Grandis World combined, creating a space to enjoy a series of new events with the following features and shops available now:
- Neo Stone Shop: Players can exchange Neo Stones for a variety of improvements that can be used to enhance items and boost character growth
- Neo Gem Shop: Neo Gems are earned by playing one of the many new mini-games, and can be used to buy special cosmetic items
- Neo Core Shop: Neo Cores can be collected by battling bosses and can be used to purchase a variety of rare items
- Neo Meso Shop: The Meso shop is stocked full of powerful items that can be purchased using Mesos
The Neo Update also includes the following updates and features:
Burning World and Tera Burning
Burning World and Tera Burning events return to support speedy player growth, allowing players to create and designate burning characters who will gain 1+2 levels each time they level up, to Lv. 150 and Lv. 200 respectively, receive additional level-up rewards, and earn the 17-Star Unique Absolab weapon.
The Better Maple Project brings a host of new improvements for overall improved gameplay including:
- The V Matrix has been improved for easier use
- Boss Battles have been improved and a new boss entry system has been added, allowing players to move to the waiting area immediately from the current channel simply by selecting the boss, difficulty and pressing “GO”
- Skill Tooltips have been widened for better legibility and understanding of skill descriptions
- Equipped item functionality has been improved, allowing players the ability to compare equipped items with other items linked in chat
- The Clean Slate Scroll has been updated, and while in possession, is changed to a Pure Clean Slate Scroll to protect the item from being destroyed when it fails
- A Notification has been added to alert players when Safeguard is automatically disabled during Star Force enhancement
- Meso Market trades that are in progress for other characters in the same world have been updated and can be viewed in addition to canceling or receiving trades
- The Meso Market’s daily listing limit has been increased to 20
- Maplers can now purchase Mu Gong's Soul Shard from the Mu Lung Dojo Point Shop
To learn more about MapleStory , please visit http://maplestory.nexon.net
Social Media: TikTok / Twitter / Instagram / Twitch / Facebook / YouTube / Website
About MapleStory https://maplestory.nexon.net
MapleStory is one of the largest and most active free-to-play, side-scrolling MMORPGs with over 13 million registered players from its Global services alone out of a total seven MapleStory services around the world. First released in North America in May 2005, the game continues to grow and evolve alongside its passionate community since launching over 16 years ago. There have been over 274 million characters created to date, which would make MapleStory the 4th highest populated country in the world.
About Nexon America Inc. https://www.nexon.com/
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005162/en/
Contact information
Nexon America
Yoonmi Park
yopark@nexon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom